Inactive Instrument

News Adherex Technologies Inc. (USA) Other OTC

Equities

CA00686R4089

End-of-day quote Other OTC Other stock markets
- ^USD	-

Apr. 23	Fennec Pharmaceuticals Insider Sold Shares Worth $414,472, According to a Recent SEC Filing	MT
Apr. 19	Fennec Pharmaceuticals Insider Sold Shares Worth $433,996, According to a Recent SEC Filing	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Fennec Pharmaceuticals Insider Sold Shares Worth $414,472, According to a Recent SEC Filing	Apr. 23	MT
Fennec Pharmaceuticals Insider Sold Shares Worth $433,996, According to a Recent SEC Filing	Apr. 19	MT
Fennec Pharmaceuticals Insider Sold Shares Worth $457,182, According to a Recent SEC Filing	Apr. 17	MT
Fennec Pharmaceuticals Insider Sold Shares Worth $958,669, According to a Recent SEC Filing	Apr. 05	MT
HC Wainwright Raises Fennec Pharmaceuticals Price Target to $18 From $17, Maintains Buy Rating	Apr. 04	MT
Fennec Pharmaceuticals Insider Sold Shares Worth $437,451, According to a Recent SEC Filing	Apr. 03	MT
Fennec Pharmaceuticals : Corporate Presentation March 2024	Mar. 30	PU
Wedbush on Fennec's Q4	Mar. 21	MT
Transcript : Fennec Pharmaceuticals Inc., 2023 Earnings Call, Mar 21, 2024	Mar. 21
Fennec Pharmaceuticals up 3.2% in US Premarket, Reports Narrower Q4 Loss of $0.10 Per Share	Mar. 21	MT
Fennec Pharmaceuticals Brief: Cited Pro forma fourth quarter cash in excess of US$55 million	Mar. 21	MT
Fennec Pharmaceuticals Brief: Achieved PEDMARK Full-Year 2023 Net Product Sales of US$21.3 Million, Including $9.7 Million in Net Product Sales in the Fourth Quarter of 2023	Mar. 21	MT
North American Morning Briefing : Investors -2-	Mar. 21	DJ
Fennec Pharmaceuticals Brief: Net losses for the fourth quarter and year ended December 31, 2023, of US$2.7 million ($0.10 per share) and $16.0 million ($0.60 per share), respectively	Mar. 21	MT
Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update	Mar. 21	GL
Fennec Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Fennec Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 21	CI
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024	Mar. 19	GL
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024	Mar. 19	AQ
Wedbush on Fennec's Deal for Pedmarqsi in EU	Mar. 18	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Adherex Technologies Inc. (USA) Other OTC

Equities

CA00686R4089

Summary

Filters